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Purpose: Enterometabolic disturbances may cause meal-related symptoms. We performed a 
functional evaluation of the intestinal microflora in patients with unexplained, self-reported 
food hypersensitivity by measuring fecal short-chain fatty acids (SCFAs).
Patients and methods: Thirty-five consecutive patients with self-reported food   hypersensitivity 
and 15 healthy volunteers of similar age, gender, and body mass index collected all feces for 
72 hours. Fecal concentrations of acetic, propionic, n-butyric, i-butyric, n-valeric, i-valeric, 
n-caproic, and i-caproic acids were analyzed by gas-liquid chromatography. Concentrations 
and excretions (output) of SCFAs in patients and controls were compared and related to gas-
trointestinal symptoms.
Results: Despite nonsignificant differences between patients and controls for both total and 
individual SCFA concentrations and excretions, n-butyric acid comprised a higher (P = 0.035) 
and acetic acid a lower (P = 0.012) proportion of total SCFA in patients compared to controls. 
There were no significant correlations between symptom scores and concentrations or excretions 
of individual or total SCFAs, but the proportion of n-butyric acid was significantly higher in 
patients with severe symptoms compared to patients with moderate symptoms (P = 0.016).
Conclusion: The results indicate an enterometabolic disturbance in patients with self-reported 
food hypersensitivity. Higher proportions of n-butyric acid may be related to abdominal   symptom 
generation, but may also protect against organic bowel disease. Further studies are needed to 
clarify these aspects.
Keywords: butyrate, dysbiosis, gut microbiota, irritable bowel syndrome, short-chain fatty 
acids
Introduction
Unexplained, self-reported food hypersensitivity is a prevalent, but poorly understood 
condition.1 Most of the patients present symptoms compatible with irritable bowel 
syndrome (IBS), and altered metabolic activity of the intestinal microflora has been 
postulated as a cause.2 Conceivably, “malfermentation” of food residues entering 
the colon may explain why intake of poorly absorbable foods provokes IBS-like 
  complaints.3 Thus, ingestion of the undigestible carbohydrate lactulose replicates 
abdominal symptoms in many patients with self-reported food hypersensitivity.4 
  Evidence that implicate the microbiota in the pathogenesis of functional gastrointestinal 
disorders is indeed emerging.5
The gut microbial community can be evaluated either by assessing its composition 
or by measuring its functions. The term microflora associated characteristics (MAC) 
has been introduced to designate the latter approach, being defined as the recording Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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of any anatomical structure or physiological, biochemical, or 
immunological function in a macroorganism, which has been 
influenced by the microflora in either an anabolic or catabolic 
way.6 Measurement of fecal short-chain fatty acids (SCFAs) 
is a recognized MAC and was utilized in the present study to 
explore whether patients with self-reported food hypersensi-
tivity display abnormal microflora-related functions.
Material and methods
Patients and controls
Patients referred to Haukeland University Hospital for 
investigation of abdominal complaints self-attributed to 
food hypersensitivity were recruited consecutively from 
  February 2008 to March 2009. They were thoroughly exam-
ined, and food allergies and other organic gastrointestinal 
diseases were ruled out by methods as described previous-
ly.7   Exclusion criteria were age below 18 years, pregnancy/
lactation, organic gastrointestinal disease, and prior use 
of antibiotics (past month). Patients were diagnosed with 
IBS according to the Rome II criteria, and gastrointestinal 
symptoms were scored (from 0 to 500) using a translated 
version of the irritable bowel symptom-severity scoring 
system (IBS-SSS), developed by Francis et al.8 In addition, 
patients were asked whether constipation or diarrhea was 
their most   bothersome symptom. Healthy volunteers were 
recruited from the   hospital staff and students at the University 
of Bergen. They were included if they considered themselves 
to be healthy, and were not further examined. They were 
excluded if they had used antibiotics during the past month. 
The study was performed in accordance with the Declara-
tion of Helsinki and approved by the Regional Committee 
for Medical Research Ethics.
Fecal sampling procedure
The participants collected all feces that passed during a 
72 h period, using one plastic box per day (volume 1000 mL; 
diameter 133 mm; reg. codes 257077 and 257078, Corporate 
Express, Oslo, Norway). They were carefully instructed to 
freeze the specimens immediately at −20°C at home, and bring 
the frozen boxes to the hospital. Total (72 h) fecal wet weight 
was noted, and a small piece of feces from each box was retained 
for SCFA measurement (stored at −20°C until analysis).
sCFA analysis
SCFA analyses were performed at Karolinska Institutet, 
Stockholm, Sweden. The fecal material was homogenized 
after addition of distilled water containing 3 mmol/L of 
2-ethylbutyric acid (as internal standard) and 0.5 mmol/L 
of H2SO4; 2 mL of the homogenate was vacuum distilled, 
according to the method of Zijlstra et al,9 as modified 
by Höverstad et al.10 The distillate was analyzed with 
gas-liquid chromatography and quantified using internal 
  standardization. Flame   ionization detection was employed. 
The results were expressed in mmol/kg wet weight. The 
following SCFAs were analyzed: acetic, propionic, i-butyric, 
n-butyric,   i-valeric, n-valeric, i-caproic, and n-caproic acids. 
A mean value based on the number of samples delivered 
was calculated for each subject and used for the statistical 
analyses.
statistics
Data were analyzed using Graphpad Prism version 5 (Graphpad 
Software Inc., San Diego, CA, USA). Data are expressed as 
mean ± standard deviation (SD), unless otherwise stated. We 
used unpaired t-tests to compare mean values between the 
groups. Categorical data were compared using Fisher’s exact 
test. Correlations were evaluated using Pearson’s correlation 
coefficient. All tests were two-tailed, and P values of less 
than 5% were considered statistically significant.
Results
subject characteristics
Forty-seven patients were referred to our hospital during the 
recruitment period. Eleven patients (3 males [M], 8 females 
[F]) refused to participate in the study (they felt that the 
procedure was too cumbersome), and one 17 year old male 
patient was too young to be included. A total of 35 patients 
were therefore studied (5 M, 30 F; mean age 36.2, range 
18–67 years; mean body mass index (BMI) 24.7, range 
16.2–41.0 kg/m2). Fifteen healthy volunteers agreed to 
participate (4 M, 11 F; mean age 32.1, range 22–68 years; 
mean BMI 23.7, range 20.1–27.8 kg/m2). Patients and 
controls were comparable with respect to gender, age, and 
BMI. None of the patients had evidence of food allergies or 
other organic diseases that could explain their symptoms. 
All patients except one male (who had abdominal pain that 
was unrelated to changes in stool frequency or stool form), 
fulfilled the Rome II criteria for having IBS. Mean habitual 
symptom score (IBS-SSS) in patients was 280.5 ± 87.4, 
and according to the suggested cut-off values,8 respec-
tively 19 and 16 patients could be classified as moderate 
(score 175–300) and severe (score . 300) cases. Twelve 
(34.3%) and 20 patients (57.1%), respectively, claimed 
that constipation and diarrhea was their predominant bowel 
disturbance, whereas the rest (n = 3; 8.6%) could not decide 
which was worse.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
67
intestinal fermentation in self-reported food hypersensitivity
Fecal samples
The 72 h fecal collection procedure was successfully 
  completed by all participants, except in two controls, who 
  collected feces for one day (24 h) only. Most of the subjects 
(27 patients and seven controls) passed feces daily, while 
some voided only two of three days (four patients and four 
controls), and some only once (four patients and two controls). 
Mean fecal wet weight (72 h) was 417.2 ± 226.6 g in patients 
and 442.3 ± 244.4 g in controls (P = 0.7). Interestingly, all 
patients who reported that constipation was their predominant 
bowel disturbance (n = 12) passed feces daily during the 
collection period, and fecal weight was not significantly 
different between patients complaining of predominant con-
stipation and patients complaining of predominant diarrhea 
(370.7 ± 297.4 g versus 447.8 ± 156.0 g; P = 0.3).
Fecal sCFAs
Total SCFA concentration in feces varied considerably from 
day to day within individuals, with estimated intra-individual 
coefficients of variation being 22.6% and 20.6% for patients 
and controls respectively. Inter-individual   coefficients of 
variation were even greater; 56.2% and 42.2% for patients and 
controls respectively. Acetic, propionic, and n-butyric acids 
were the dominating SCFAs in all subjects. Iso-caproic acid 
was detectable in 11 patients and five controls, whereas 
n-caproic acid was absent in one patient and one control. 
There were no significant differences in either concentrations 
or excretions (output) between patients and controls 
(Table 1). There were several significant correlations between 
the individual SCFA concentrations (data not shown), similar 
to what has been reported previously.11,12 Neither BMI nor 
fecal wet weight was significantly correlated to SCFA con-
centrations, and there was no difference between males and 
females. There was no difference in SCFA concentrations 
or excretions between patients complaining of predominant 
constipation and patients complaining of predominant 
  diarrhea. There was no correlation between   individual or total 
SCFA concentrations or excretions and symptom scores in 
the patient group. Interestingly, the   proportional distribution 
of   individual SCFA to total SCFA was different between 
Table 1 Fecal sCFAs in patients with self-reported food hypersensitivity and healthy controls
SCFA concentration (mmol/kg wet weight) Patients (n = 35) Controls (n = 15) P value
Acetic acid 86.84 ± 59.08 107.30 ± 53.46 0.25
  % of total sCFA concentration 69.37 ± 9.21 76.91 ± 9.56 0.01*
Propionic acid 11.53 ± 6.44 9.71 ± 3.28 0.31
  % of total sCFA concentration 10.37 ± 3.52 8.46 ± 3.70 0.09
i-butyric acid 1.80 ± 0.82 1.47 ± 0.47 0.15
  % of total sCFA concentration 1.89 ± 0.94 1.38 ± 0.67 0.06
n-butyric acid 14.91 ± 9.32 11.32 ± 5.58 0.17
  % of total sCFA concentration 13.12 ± 5.76 9.47 ± 4.60 0.04*
i-valeric acid 2.43 ± 1.20 2.03 ± 0.71 0.23
  % of total sCFA concentration 2.71 ± 1.54 2.05 ± 1.22 0.15
n-valeric acid 1.77 ± 1.01 1.45 ± 0.45 0.25
  % of total sCFA concentration 1.80 ± 0.94 1.34 ± 0.76 0.10
i-caproic acid 0.03 ± 0.06 0.02 ± 0.03 0.27
  % of total sCFA concentration 0.03 ± 0.05 0.01 ± 0.03 0.27
n-caproic acid 0.70 ± 0.92 0.42 ± 0.53 0.31
  % of total sCFA concentration 0.70 ± 0.81 0.38 ± 0.53 0.16
Total sCFA 120.00 ± 67.40 133.80 ± 56.48 0.49
SCFA excretion (mmol/72 h) Patients (n = 35) Controls (n = 13) P value
Acetic acid 39.07 ± 35.33 48.08 ± 47.19 0.48
Propionic acid 5.31 ± 4.70 4.40 ± 3.44 0.53
i-butyric acid 0.76 ± 0.53 0.57 ± 0.32 0.25
n-butyric acid 6.72 ± 5.71 5.61 ± 5.35 0.55
i-valeric acid 1.00 ± 0.67 0.77 ± 0.31 0.23
n-valeric acid 0.76 ± 0.64 0.61 ± 0.36 0.44
i-caproic acid 0.02 ± 0.03 0.01 ± 0.01 0.27
n-caproic acid 0.29 ± 0.46 0.17 ± 0.19 0.37
Total sCFA 53.92 ± 44.23 60.23 ± 55.15 0.68
Notes: Data are presented as mean ± sD.
*Denotes statistically significant differences between patients and controls.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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patients and controls, with a   significantly lower percentage 
of acetic acid (P = 0.012) and higher percentage of n-butyric 
acid in the patients (P = 0.035). Although there was no cor-
relation between the percentage of acetic acid or n-butyric 
acid and symptom scores, the proportion of n-butyric acid 
was higher in patients classified as severe cases according 
to IBS-SSS than in patients classified as moderate cases 
(P = 0.016) (Figure 1).
Discussion
The appearance of SCFAs in feces reflects a complex inter-
play between host, diet, and microbes, and an altered SCFA 
profile may signify enterometabolic changes that could be 
related to functional gastrointestinal symptoms, either as 
a cause or a consequence. In the present study, patients 
with unexplained, self-reported food hypersensitivity and 
abdominal complaints had higher proportions of n-butyric 
acid and lower proportions of acetic acid in fecal samples than 
healthy controls. These data are partly analogous to findings 
in patients with IBS reported by other groups,13,14 although 
not all.15,16 In the following section, possible implications of 
our results are discussed.
Weaver et al17 argue that ratios of individual SCFA 
concentrations to total SCFA concentration are better indi-
cators of microbial fermentation patterns than absolute 
quantities due to variations in the liquid content of samples. 
In healthy volunteers, concentrations of the major SCFAs 
correlate positively with fecal water content.12 This may be 
explained by variations in intestinal transit time, as a rapid 
passage could impair absorption of both water and SCFAs. 
This view is supported by El Oufir et al.18 Also, the recently 
reported association between obesity and high total SCFA 
concentration19 may be explained by decreased intestinal 
transit time.20 The relationship between fecal water content 
and SCFA concentration does not apply for all conditions, 
however, as antibiotic-associated diarrhea is characterized by 
low levels of SCFA concentrations due to suppressed micro-
bial fermentation.21 Mortensen et al22 demonstrated that IBS 
patients with constipation have low fecal SCFA concentra-
tions and IBS patients with diarrhea have high fecal SCFA 
concentrations. That fecal weights and SCFA concentrations 
in our study were similar between patients complaining 
of predominant constipation and patients complaining of 
predominant diarrhea is therefore interesting, and may 
question the validity of the patients’ claims about bowel 
habits.23 Constipation and diarrhea should be considered as 
signs rather than symptoms, and our results demonstrate the 
value of quantifying stool weight objectively. In the present 
study, neither fecal wet weight nor BMI was significantly 
related to SCFA concentrations. Hence, it seems unlikely 
that the different SCFA proportions found between patients 
and controls in our study could be explained by differences 
in intestinal transit times solely.
Acetic, propionic, and n-butyric acids are mainly derived 
from proximal colonic fermentation of carbohydrates 
escaping small intestinal digestion and absorption. That 
dietary carbohydrates plays an important role in yielding 
SCFAs was convincingly demonstrated in a recent study by 
Duncan et al,24 showing a marked reduction of both butyrate 
and butyrogenic bacteria in fecal samples from obese indi-
viduals after introduction of a carbohydrate restricted diet. 
  Malabsorption of starch, in particular, shifts the SCFA dis-
tribution in favor of n-butyric acid.25 The ability to digest 
and absorb starch shows marked inter-individual variation, 
possibly on a genetic basis,26 but whether patients with self-
reported food hypersensitivity malabsorb more starch than 
healthy individuals is presently unknown.   Conceivably, aber-
rations of small intestinal motility, such as rapid small intes-
tinal transit induced by psychological stress27 and possibly 
atopic “IgE arming” of intestinal mast cells,28 may increase 
colonic delivery of undigested starch. Also, deficiency of 
alpha glucosidase has been suggested as a putative cause 
of IBS,29 but the finding has not been followed up in proper 
studies. We acknowledge that the results of our study, ie, high 
proportions of n-butyric acid and low proportions of acetic 
acid in fecal samples from patients with self-reported food 
hypersensitivity, could reflect dietary differences between 
patients and controls. However, we have previously demon-
strated that patients with self-reported food hypersensitivity 
eat similar amounts of whole grain bread, fruit, and raw 
vegetables as healthy controls.30
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Figure 1 SCFA distribution in fecal samples from patients classified as moderate 
cases (n = 19) and patients classified as severe cases (n = 16). individual sCFA are 
shown as mean percentages of total sCFA concentration. note, the proportion of 
n-butyric acid is higher in severe cases versus moderate cases (P = 0.016). Minor 
sCFAs = sum of percentages of i-butyric, i-valeric, n-valeric, i-caproic, and n-caproic 
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Our results, indicating altered intestinal fermentation, are 
consistent with an enterometabolic disturbance in patients 
with self-reported food hypersensitivity, conceivably 
associated with IBS-like symptoms. There is evidence 
that the intestinal microflora is altered in IBS patients 
compared to controls.31 Decreased numbers of lactobacilli 
and bifidobacteria have been reported,32 and, interestingly, 
neither of these genera are capable of producing n-butyric 
acid.33,34 These observations are compatible with our finding 
of increased proportions of n-butyric acid in fecal samples. 
In animal models, n-butyric acid may be directly involved in 
symptom generation,35 although preliminary human studies 
does not support this view.36 That neither concentrations or 
excretions, nor percentages of any of the analyzed SCFAs, 
were correlated to symptom scores in our study seems 
to argue against a direct effect of SCFAs. Still, patients 
classified as severe cases had higher values of n-butyric acid 
in relation to total SCFA than patients with less symptoms – 
a finding in accordance with data from other groups.37 The 
results of a ”butyrogenic” diet trial in IBS patients are eagerly 
awaited.38
Intriguingly, high proportions of n-butyric acid may 
protect against organic bowel diseases, both inflammatory 
and neoplastic.39 Regulation of gene expression through 
inhibition of histone deacetylase seem to be an important 
mechanism whereby butyrate exert immuno-modulatory 
and anticarcinogenic effects.39 Although most of our 
knowledge concerning the protective role of n-butyric acid 
is based on animal and in vitro studies, lower proportions 
of n-butyric acid and higher proportions of acetic acid have 
been demonstrated in enema samples from patients with 
adenomatous polyps and colonic cancer compared to healthy 
controls.17 Importantly, Chey et al40 recently observed a 
considerably lower prevalence of colorectal adenomas in 
IBS patients compared to asymptomatic controls. In this 
regard, and based on our results, it is tempting to speculate 
that having IBS is actually advantageous. Whether IBS 
has a protective effect against organic bowel diseases – via 
intestinal microbiota skewed to produce n-butyric acid – 
certainly deserves to be investigated further.
Conclusion
We conclude that the fecal SCFA profile seems to be 
altered in patients with unexplained, self-reported food 
hypersensitivity. This may reflect considerable alterations in 
the intestinal microflora. High proportions of n-butyric acid 
are conceivably related to abdominal symptom generation, 
but may at the same time offer protection against colorectal 
inflammation and neoplasia. These aspects should be 
addressed in future studies.
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